• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia.
CONCLUSIONS: There is no evidence to support the use of low-dose aspirin or other NSAIDs of any class (celecoxib, rofecoxib or naproxen) for the prevention of dementia, but there was evidence of harm. Although there were limitations in the available evidence, it seems unlikely that there is any need for further trials of low-dose aspirin for dementia prevention. If future studies of NSAIDs for dementia prevention are planned, they will need to be cognisant of the safety concerns arising from the existing studies. PMID: 32352165 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - April 29, 2020 Category: General Medicine Authors: Jordan F, Quinn TJ, McGuinness B, Passmore P, Kelly JP, Tudur Smith C, Murphy K, Devane D Tags: Cochrane Database Syst Rev Source Type: research

Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study
Publication date: Available online 13 June 2017 Source:The Lancet Author(s): Linxin Li, Olivia C Geraghty, Ziyah Mehta, Peter M Rothwell Background Lifelong antiplatelet treatment is recommended after ischaemic vascular events, on the basis of trials done mainly in patients younger than 75 years. Upper gastrointestinal bleeding is a serious complication, but had low case fatality in trials of aspirin and is not generally thought to cause long-term disability. Consequently, although co-prescription of proton-pump inhibitors (PPIs) reduces upper gastrointestinal bleeds by 70–90%, uptake is low and guidelines are conflicti...
Source: The Lancet - June 15, 2017 Category: General Medicine Source Type: research

WITHDRAWN: Chuanxiong preparations for preventing stroke.
CONCLUSIONS: Nao-an capsule may be a choice for the primary prevention of stroke. However, the design of the study providing this evidence means that there was potential for results to have been affected by bias from the way participants may have been selected, or from investigators' conflicts of interests. There was a lack of description of the methodology in the two other studies therefore evidence from these was considered too weak to draw any firm conclusions. Further high quality research is required. PMID: 27258581 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - June 2, 2016 Category: Journals (General) Authors: Yang X, Zeng X, Wu T Tags: Cochrane Database Syst Rev Source Type: research

Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke.
CONCLUSIONS: The available trial evidence showed that, for individuals with acute ischaemic stroke, GP IIb-IIIa inhibitors are associated with a significant risk of intracranial haemorrhage with no evidence of any reduction in death or disability in survivors. These data do not support their routine use in clinical practice. The conclusion is driven by trials of Abciximab, which contributed 89% of the total number of study participants considered. PMID: 24609741 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - March 8, 2014 Category: Journals (General) Authors: Ciccone A, Motto C, Abraha I, Cozzolino F, Santilli I Tags: Cochrane Database Syst Rev Source Type: research

Use of antiplatelet drugs in stroke prevention: time for a rethink?
Worldwide, 15 million people suffer stroke each year from which a third die and a further third sustain severe disability, with ischaemic events accounting for ~80% of all strokes.1 The annual estimated economic burden of stroke is 64.1 billion in Europe alone.2 While recent major investments in acute stroke services have focused on thrombolysis and hospitalisation in dedicated stroke wards, we believe that primary and secondary stroke prevention should remain of utmost importance in a disease that carries such serious permanent neurological sequelae. Antiplatelet agents such as aspirin, diypridamole or clodpidogrel are ph...
Source: Postgraduate Medical Journal - May 17, 2013 Category: Journals (General) Authors: Loke, Y. K., White, J. R., Bettencourt-Silva, J. H., Potter, J. F., Myint, P. K. Tags: GI bleeding, Drugs: cardiovascular system, Stroke, Ischaemic heart disease, Epidemiology Editorials Source Type: research